Opinion|Videos|October 14, 2024
Utilization of Fecal Microbiota Transplant Products in Clinical Practice
Experts on the treatment of patients with C. difficile infections provide insights on the implementation of fecal microbiota transplant products into clinical practices.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- For clinicians who don’t have microbiota-based therapy available in their practice, what do they need to do to get started?
- What are some practical tips on when and how to get started with FMT for patients showing signs of recurrence?
Advertisement
Related to this article
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.
Advertisement
Advertisement
Trending on Contagion Live
1
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
2
Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
3
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
4
Measles Update: October 30, 2026
5